Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progran...
Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia
About this item
Full title
Author / Creator
Rosenthal, Zachary C. , Fass, Daniel M. , Payne, N. Connor , She, Angela , Patnaik, Debasis , Hennig, Krista M. , Tesla, Rachel , Werthmann, Gordon C. , Guhl, Charlotte , Reis, Surya A. , Wang, Xiaoyu , Chen, Yueting , Placzek, Michael , Williams, Noelle S. , Hooker, Jacob , Herz, Joachim , Mazitschek, Ralph and Haggarty, Stephen J.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Frontotemporal dementia (FTD) is a debilitating neurodegenerative disorder with currently no disease-modifying treatment options available. Mutations in
GRN
are one of the most common genetic causes of FTD, near ubiquitously resulting in progranulin (PGRN) haploinsufficiency. Small molecules that can restore PGRN protein to healthy levels in...
Alternative Titles
Full title
Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0ce6be333ade4397a3f955c44b12062e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0ce6be333ade4397a3f955c44b12062e
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-024-59110-7
